Tetracaine & Oxymetazoline

BreastfeedingGeriatricPediatric

FDA APPROVAL DATE: 06/29/2016

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Beta blockers, MAOIs, Other intranasal products, Tricyclic antidepressants

PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk

For intranasal use only. See separate entry for oxymetazoline as topical formulation.

Our database has 18 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
OCULAR
OTHER


Page last updated 02/02/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric